argenx (NASDAQ: ARGX) — Company Overview, News & Financial Data
argenx is a biotechnology company developing antibody-based therapies for autoimmune diseases and cancer, focusing on innovative patient solutions.
argenx
argenx is a global immunology company focused on improving the lives of patients suffering from severe autoimmune diseases. The company discovers, develops, and commercializes novel antibody-based therapies designed to target autoimmune pathology through its proprietary antibody innovation ecosystem. Its primary product, VYVGART (efgartigimod), is a neonatal Fc receptor (FcRn) blocker approved for the treatment of generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, with additional formulations including VYVGART Hytrulo. argenx collaborates with academic and industrial research partners to discover novel targets, advance disease pathways, and progress candidate therapies through clinical development across global markets.
Snapshot
Operations
Products and/or services of argenx
- Intravenous Neonatal Fc Receptor Blockers: Intravenous formulations targeting neonatal Fc receptors to reduce pathogenic IgG antibodies, approved for treating generalized myasthenia gravis in adult patients across major pharmaceutical markets including the United States, Europe, Japan, and Canada.
- Subcutaneous Neonatal Fc Receptor Blockers: Subcutaneous co-formulated antibody therapeutics combined with recombinant human hyaluronidase, approved for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy to enable self-administration or reduced infusion duration in clinical settings.
- Complement C2 Inhibitors: Humanized sweeping monoclonal antibodies designed to selectively inhibit complement component C2 and downstream complement pathway activation, currently undergoing clinical trials and development for severe IgM-driven autoimmune conditions in global patient populations.
- Antibody Innovation Ecosystem: Collaborative research initiatives with academic medical centers and biopharmaceutical partners to discover novel target pathways, engineer differentiated monoclonal antibody candidates, and translate early-stage immunology discoveries into clinical pipelines.
- Externally Sponsored Research Programs: Global investigator-initiated clinical trial collaborations evaluating neonatal Fc receptor inhibition and complement-targeting therapeutic candidates across expanded autoimmune indications, including hematologic, neuromuscular, nephrologic, and dermatologic disease categories in patient populations worldwide.
- Commercial Distribution and Market Access: Integrated commercialization infrastructure, specialty medical operations, and global distribution networks delivering target-specific immunology therapeutics to patients, medical centers, and healthcare providers across North America, Europe, Asia-Pacific, and Latin America.
argenx executive team
- Mr. Timothy Van Hauwermeiren EMBA, M.Sc.Co-Founder, CEO & Executive Director
- Mr. Karl GubitzChief Financial Officer
- Ms. Karen MasseyChief Operating Officer
- Dr. Peter UlrichtsChief Scientific Officer
- Ms. Malini MoorthyGeneral Counsel
- Mr. Arjen Lemmen M.Sc.Vice President of Corporate Development & Strategy
- Ms. Andria WilkGlobal Head of Quality
- Dr. Luc TruyenChief Medical Officer
- Prof. Hans de Haard Ir, Ph.D.Co-Founder & Member of Board Advisors
- Mr. Filip BorgionsChief Technology Innovation Officer